4.7 Article

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

期刊

CLINICAL CANCER RESEARCH
卷 23, 期 14, 页码 3802-3812

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-16-1501

关键词

-

类别

资金

  1. NIH [F31CA186736, T32GM008424, K99CA193734, R01CA184502]
  2. Magee-Womens Research Foundation
  3. University of Pittsburgh Cancer Institute (UPCI)
  4. ARCS Foundation
  5. Department of Defense [CDMRP W81XWH-13-1-0205]
  6. Ovarian Cancer Academy Early Career Investigator Award [W81XWH-15-0194]
  7. RPCI-UPCI SPORE [5P50CA159981-03]
  8. Mayo Clinic SPORE [2P50CA136393]
  9. [NIHP30CA047904]

向作者/读者索取更多资源

Purpose: High-grade serous ovarian cancer (HGSOC) is an aggressive disease with few available targeted therapies. Despite high expression of estrogen receptor-alpha (ER alpha) in approximately 80% of HGSOC and some small but promising clinical trials of endocrine therapy, ER alpha has been understudied as a target in this disease. We sought to identify hormone-responsive, ER alpha-dependent HGSOC. Experimental Design: We characterized endocrine response in HGSOC cells across culture conditions [two-dimensional (2D), three-dimensional (3D), forced suspension] and in patient-derived xenograft (PDX) explants, assessing proliferation and gene expression. Estrogen-regulated transcriptome data were overlapped with public datasets to develop a comprehensive panel of ER alpha target genes. Expression of this panel and ER alpha H-score were assessed in HGSOC samples from patients who received endocrine therapy. Time on endocrine therapy was used as a surrogate for clinical response. Results: Proliferation is ER alpha-regulated in HGSOC cells in vitro and in vivo, and is partly dependent on 3D context. Transcriptomic studies identified genes shared by cell lines and PDX explants as ER alpha targets. The selective ER alpha downregulator (SERD) fulvestrant is more effective than tamoxifen in blocking ER alpha action. ER alpha H-score is predictive of efficacy of endocrine therapy, and this prediction is further improved by inclusion of target gene expression, particularly IGFBP3. Conclusions: Laboratory models corroborate intertumor heterogeneity of endocrine response in HGSOC but identify features associated with functional ER alpha and endocrine responsiveness. Assessing ER alpha function (e.g., IGFBP3 expression) in conjunction with H-score may help select patients who would benefit from endocrine therapy. Preclinical data suggest that SERDs might be more effective than tamoxifen. (C) 2017 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据